Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 303

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 303
---
565)(24,439)Other income:Interest income3,667 2,566 6,667 3,698 Other income171 174 348 342 Total other income3,838 2,740 7,015 4,040 Net loss$(18,068)$(8,552)$(34,550)$(20,399)Net loss per share, basic and diluted$(0.41)$(2.71)$(0.98)$(6.54)Weighted-average common shares outstanding, basic and diluted44,116,997 3,159,815 35,404,928 3,121,225 Comprehensive loss:Net loss$(18,068)$(8,552)$(34,550)$(20,399)Unrealized loss on marketable securities(118)(148)(185)(156)Total other comprehensive loss(118)(148)(185)(156)Comprehensive loss$(18,186)$(8,700)$(34,735)$(20,555)

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-3

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share amounts) 

(Unaudited)

Series SeedSeries ASeries BSeries C Common Stock AdditionalPaid-InCapitalAccumulatedOtherComprehensiveLossAccumulatedDeficitTotalStockholders’DeficitPreferred Stock Preferred StockPreferred Stock Preferred Stock SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 20233,963,963$13,014 5,704,161$25,235 11,370,621$110,791 —$— 3,050,863$2 $4,515 $— $(119,398)$(114,881)Issuance of Series C Preferred Stock, net of issuance costs of $528—— —— —— 18,628,970181,328 —— — — — — Exercise of common stock options—— —— —— —— 821— 5 — — 5 Vesting of restricted common stock awards—— —— —— —— 51,1851 — — — 1 Stock-based compensation expense—— —— —— ——